Tag:

VaxInnate

Latest Headlines

Latest Headlines

UPDATED: VaxInnate brings seasonal flu vaccine into Phase II

June 4, 2015 | By
Each year, health authorities make predictions about which flu strains will be the most common. But if the strains mutate, flu vaccines are powerless to prevent infection. Enter VaxInnate, which is taking its quick-to-produce quadrivalent seasonal flu vaccine into Phase II safety trials.

VaxInnate reaps $53M for flu jab trials on BARDA contract extension

February 19, 2015 | By
The U.S. Department of Health and Human Services apparently likes what it's seen from a 5-year contract with VaxInnate. Its Biomedical Advanced Research and Development Authority (BARDA) has extended the contract's base period with the flu vaccine maker, a move that allows for the use of $53 million.

VaxInnate bird flu shot flies into Phase I

June 14, 2012 | By
VaxInnate's VAX161, the company's vaccine in development to protect against a bird flu pandemic, has moved into Phase I trials.

Interview: VaxInnate plots its future following HHS contract

March 31, 2011 | By
"VaxInnate: We're fast, cheap and easy," jokes CSO Alan Shaw (pictured, left). And that's just what the HHS likes about the company. Last month the agency granted the Cranbury,...

Interview: Novavax's CEO discusses HHS flu vaccine funding

March 3, 2011 | By
Earlier this week, the HHS doubled down on new vaccine technology. The government granted Maryland-based Novavax a contract worth up to $179.1 million, while Cranbury, NJ's VaxInnate picked up a

Novavax, VaxInnate win $215M to develop better pandemic vaccines

FierceBiotech | March 1, 2011
The feds drive to whip up a bigger, faster supply of flu vaccine to fight pandemics has triggered a pair of new contracts initially totaling $215 million for Novavax and VaxInnate. Novavax shares

VaxInnate nabs $30M in fourth venture round

FierceBiotech | May 6, 2009
The Wellcome Trust has signed on as a new investor of VaxInnate, leading a $30 million Series D for the vaccine developer as it pursues a more efficient approach to the field. New Leaf Venture

Universal flu vax works in early-stage trial

August 28, 2008 | By
VaxInnate's universal flu vaccine has produced positive results in an early stage trial at the University of Texas at Galveston. Researchers there said that VaxInnate's M2e universal vaccine
Related Tags

VaxInnate Press Releases

  • Two New Executives Join VaxInnate Management Team
  • VaxInnate Licenses Recombinant Flu Vaccines to CJ CheilJedang Corporation of South Korea
  • VaxInnate Awarded Contract by the U.S. Government To Develop Recombinant Seasonal and Pandemic Flu Vaccines
  • VaxInnate's Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study
  • VaxInnate's Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009
Press Releases
  • FDA's Arthritis Advisory Committee Recommends Approval of Celltrion's CT-P13, a Proposed Biosimilar Infliximab, for All Indications
  • GeoVax Labs Inc. (GOVX.OB) To Develop Vaccine Against Zika Virus
  • Quanterix's Simoa Technology Demonstrates Ability to Analyze Single Cancer Cells
  • First Patient Treated with Medtronic Valiant TAAA Stent Graft System in Thoracoabdominal Aortic Aneurysm Study
  • Hospitals hire Philips to predict fall risk for elderly patients; Withings launches personalized blood pressure app;
  • More Press Releases
Sponsored Links